Cloxazolam is an agonist of GABA-A receptor that was developed in Japan for the treatment of anxiety-disorders. The drug was marketed in Europe under the names Sepazon, Olcadil, Akton and Lubalix.
Cloxazolam is a benzodiazepine with anxiolytic, sedative/hypnotic, muscle relaxant, and antiepileptic effects. It is marketed in the Argentina, Australia, Portugal, Belgium, Switzerland, Luxembourg, Germany, Taiwan and Japan mainly for anti-anxiety. Although less commonly noted, it has also been reported as clinically effective in the treatment of depression, schizophrenia, and neurosis. Has also been studied in Japan as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness. Used primarily as an anti-anxiety agent. Typically used short term, and may be given as a single dose of up to 100mcg/kg to reduce anxiety and tension experienced prior to surgery.
Cloxazolam is a long acting benzodiazepine. Alcohol used in combination may enhance sedation or cause potentially fatal respiratory/cardiovascular depression.
Benzodiazepine derivate that is metabolised into Delorazepam. Which is where most of its effects come from.
|All ROAs:||15-45 minutes||7-12 hours||4-12 hours|
It is not widely used:
As of August 2018 it was marketed in Belgium, Luxembourg, Portugal, Brazil, and Japan.
- A benzodiazepine derivative
- It has anxiolytic, sedative, and anticonvulsant properties
Mexazolam and Alprazolam in the Treatment of Generalised Anxiety Disorder: A Double-Blind, Randomised Clinical Trial - The three major types of drugs considered in the management of GAD are buspirone, benzodiazepines and selective serotonin reuptake inhibitors (SSRI).  The purpose of this trial was to compare ...
Saturday February 04, 2023 - medscape.com
|Depressants | Link to this page|